# Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

> **NCT00001059** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 120 (—)

## Conditions studied

- Sarcoma, Kaposi
- HIV Infections

## Interventions

- **DRUG:** Doxorubicin hydrochloride (liposomal)
- **DRUG:** Filgrastim
- **DRUG:** Bleomycin sulfate
- **DRUG:** Vincristine sulfate

## Key facts

- **NCT ID:** NCT00001059
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1998-08
- **Target enrollment:** 120 (—)
- **Last updated:** 2012-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001059, "Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00001059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*